An Australian stem cell and regenerative medicine company
About Us
About Us
What We Do
Board Of Directors
Management
Scientific Advisors
Corporate Governance
Company History
Clinical Development
Graft-versus-host-disease
Osteoarthritis
Acute respiratory distress syndrome
Diabetic Wounds
Renal transplantation
Pre-clinical Development
Asthma
Heart Attack
Coronary Artery Disease
Brain Cancer
Sepsis
Critical Limb Ischemia
Idiopathic pulmonary fibrosis
Science & Technology
Cymerus Technology
About MSCs
About iPSCs
Science Publications
Investors
Stock Information
ASX Announcements
Financial Reports
Presentations
Corporate Governance
Analyst Research
Investor FAQs
Right to Receive Documents
Newsroom
FAQ
Company FAQs
Investor FAQs
Contact Us
ASX Announcements
17 Nov 2017
Chairman's Annual General Meeting Address
14 Nov 2017
Company Investor Presentation
14 Nov 2017
Enrolment Completed in 1st Cohort of Cynata Clinical Trial
27 Oct 2017
September 2017 Quarterly Report
10 Oct 2017
Van Leeuwenhoeck Institute Updates Cynata Research Coverage
09 Oct 2017
Annual Report to Shareholders
09 Oct 2017
Notice of Annual General Meeting/Proxy Form
09 Oct 2017
Cynata to Increase Exposure in Japan
27 Sep 2017
US Patent Granted for Cynata Cymerus Technology
10 Sep 2017
HC Wainwright & Co Updates Cynata Research Coverage
31 Aug 2017
Health Canada Meeting Advances CYP Global Development Plans
24 Aug 2017
Appendix 4G
24 Aug 2017
Appendix 4E & Financial Statements
23 Aug 2017
Positive Data from CYP MSCs in 2nd Preclinical Asthma Study
07 Aug 2017
Appendix 3B
28 Jul 2017
June 2017 Quarterly Report
24 Jul 2017
NDF's Stuart Roberts Initiates Cynata Research Coverage
04 Jul 2017
FDA Meeting Provides Clear Path for US Development Plans
04 Jul 2017
Change of Address
27 Jun 2017
Cynata Therapeutics GvHD Clinical Trial & Corporate Progress
22 Jun 2017
CYP MSC Data in Asthma Model Published in Scientific Journal
20 Jun 2017
Cynata Files New Patent Application for Cymerus in Oncology
19 Jun 2017
United States Patent for Core Cynata Technology
06 Jun 2017
Van Leeuwenhoeck Institute Initiates CYP Research Coverage
04 Jun 2017
Appendix 3Y-Peter Webse
04 Jun 2017
Correction to date in Appendix 3Y Lodged 26 May 2017
29 May 2017
Cynata Investor Presentation May 2017
25 May 2017
Appendix 3Y-Paul Wotton
17 May 2017
Appendix 3Y-John Chiplin
15 May 2017
Treatment Commences in Cynata's World First Clinical Trial
10 May 2017
Interview with UK Chief Investigator in Cynata Clinical Trial
07 May 2017
Shaw & Partners Initiates Cynata Research Coverage
07 May 2017
Appendix 3Y-Paul Wotton
03 May 2017
Cyanta Presentation & Webcast
03 May 2017
Appendix 3Y-Stewart Washer
26 Apr 2017
March 2017 Quarterly Report
18 Apr 2017
Cynata Advances to Pre-IND Meeting with US FDA
11 Apr 2017
CYP Files for New Patent for Oncology Applications
10 Apr 2017
CYP in Collaboration on Acute Respiratory Distress Syndrome
03 Apr 2017
Appendix 3Y-Ross Macdonald
30 Mar 2017
Cynata Partner apceth GmbH & Co Completes Cymerus Evaluation
10 Mar 2017
Proactive Investor Conference Presentation
01 Mar 2017
CYP Advances Development of Cymerus for Treatment of Asthma
27 Feb 2017
Dr Paul Wotton Appointed as Chairman of Cynata
27 Feb 2017
Appendix 4D & Half-Year Financial Statements
24 Feb 2017
Change in substantial holding
19 Feb 2017
Becoming a substantial holder
05 Feb 2017
Final GvHD Preclinical Report Confirms Treatment Benefit
01 Feb 2017
Positive Preliminary Data from Preclinical Heart Attack Study
30 Jan 2017
Notice Under Section 708A
‹
1
2
3
4
5
6
7
8
9
10
11
›